5-Fluorouracil Pharmacokinetics: Causes for Variability and Strategies for Modulation in Cancer Chemotherapy
- 1 January 1999
- journal article
- review article
- Published by Taylor & Francis in Cancer Investigation
- Vol. 17 (7) , 494-506
- https://doi.org/10.3109/07357909909032859
Abstract
No abstract availableThis publication has 88 references indexed in Scilit:
- A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiencyJournal of Inherited Metabolic Disease, 1996
- The role of interferon-α as a modulator of fluorouracil and leucovorinEuropean Journal Of Cancer, 1995
- Dihydropyrimidine dehydrogenase activity in cancer patientsEuropean Journal Of Cancer, 1993
- Clinical Pharmacology of 5-FluorouracilClinical Pharmacokinetics, 1989
- Oral 5-Fluorouracil in Psoriasis: Pharmacokinetic-Pharmacodynamic RelationshipsPharmacology, 1989
- Salivary excretion of 5-fluorouracil(5-FU). III. Non-linear kinetics of salivary excretion of 5-FU following bolus intravenous administration in rats.CHEMICAL & PHARMACEUTICAL BULLETIN, 1988
- Intestinal absorption characteristics of 5-fluorouracil, ftorafur and 6-mercaptopurine in rats.CHEMICAL & PHARMACEUTICAL BULLETIN, 1986
- Familial Pyrimidinemia and Pyrimidinuria Associated with Severe Fluorouracil ToxicityNew England Journal of Medicine, 1985
- Activation of 5'-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors.CHEMICAL & PHARMACEUTICAL BULLETIN, 1983
- Fluorouracil Therapy in Patients With Carcinoma of the Large BowelClinical Pharmacokinetics, 1978